Recently, there has been an interesting report linking PDHK1 and BRAF in melanoma.22 It has also been shown that activation PDHK by phosphorylation or by upregulation of gene expression is induced by different oncogenes such as MYC, HIF-1, FGFR1 or BCR-ABL.23 Given the importance of oncogenic KRAS in maintaining the glycolytic phenotype in cancer cells, we decided to investigate the role of PDHKs and PDH activation in KRAS mutant cancer models. The gene discussed is PDP1; the disease is melanoma.